At Pfizer, ConcertAI’s work will cover investigational and approved treatments, across both solid and blood tumors. The project will also look to identify new patient subpopulations for combination cancer therapy trials and includes plans to design and conduct real-world outcomes studies using synthetic control arms, with the first results expected early next year.